Radyus Research and Dt&CRO Join Forces to Pave Way for South Korean Biotech Companies into the U.S. Market

ATLANTA, May 7, 2024 /PRNewswire/ — Radyus Research, a global drug development organization from Atlanta, Georgia, is excited to announce a pivotal strategic partnership with Dt&CRO, a leading South Korean contract research organization (CRO). This collaboration aims to assist South Korean biotech companies in entering the U.S. market by offering integrated services for drug development planning, regulatory strategy, IND filings, and clinical trial management.

Dt&CRO company logo
Dt&CRO company logo

The partnership between Radyus Research and Dt&CRO marks a significant milestone in global biotech collaboration, providing a streamlined pathway for South Korean biotech innovators to access the lucrative U.S. pharma market. Leveraging Radyus Research’s expertise in navigating the complex regulatory landscape and managing preclinical and early-stage clinical trials in the United States, South Korean biotech companies can expedite their entry into this key market.

“At Radyus Research, we are thrilled to partner with Dt&CRO to empower their sponsor companies, which are ambitious and innovative biotech companies from South Korea,” said Marta New, CEO of Radyus Research. “Our collaboration will provide invaluable support and guidance, enabling South Korean innovators to navigate regulatory processes, initiate IND applications, and conduct first-in-human trials in the U.S. These critical steps are essential for South Korean biotech companies to establish a strong presence in this market and attract investment from international stakeholders.”

In return, Radyus Research will rely on Dt&CRO for non-GLP and GLP laboratory testing services tailored to Asia based clients. This reciprocal arrangement further enhances the partnership’s synergy, fostering a collaborative environment conducive to innovation and growth in the global biotech industry.

“We are excited to collaborate with Radyus Research to facilitate the expansion of South Korean biotech companies into the U.S. market,” said Mr. Chaegyu Park, CEO of Dt&CRO. “By combining our expertise in laboratory testing with Radyus Research’s comprehensive support for drug development and regulatory strategy, we can offer a holistic solution that meets the needs of biotech innovators in South Korea and enhances our global CRO competitiveness.”

The partnership between Radyus Research and Dt&CRO exemplifies a commitment to fostering innovation, collaboration, and global growth in the biotech industry. Together, they aim to accelerate the development and commercialization of breakthrough therapies that address unmet medical needs and improve patient outcomes worldwide.

About Radyus Research:

Radyus Research is a drug development organization dedicated to accelerating clients’ drug programs into the clinic. With a commitment to excellence and innovation, Radyus Research offers a range of services aimed at providing comprehensive drug development planning, regulatory filings, and clinical trial management. We act as an operating R&D partner to biotech companies, academic startups, and seed venture capital firms. Most clients start working with us during lead optimization and candidate selection phases, and we manage their programs through IND-enabling studies, IND application and initiation of first in human trials. Our extensive expertise spans various modalities in immunology, oncology, infectious diseases, metabolic diseases, and neurosciences. We are based in Atlanta, Georgia, serving clients across the globe in over 12 countries.

About Dt&CRO:

Dt&CRO is a leading preclinical CRO based in South Korea, specializing in providing global pharmaceutical companies with a wide range of CRO services comprehensive of non-clinical efficacy, GLP toxicology testing, PK testing, bioanalysis, bioequivalence, clinical trials, and licensing consultation in Asia. With a commitment to excellence and innovation, as well as its expertise in pharmaceuticals, chemicals, health-functioning food, cosmetics, and medical devices, Dt&CRO plays a vital role in advancing drug development and improving patient care on a global scale.

SOURCE Radyus Research

Georgia Life Sciences Weighs In on PBM and 340B Policy

October 5, 2026
Georgia Life Sciences has submitted written comments to the Georgia House Study Committee on Pharmacy Benefits Managers and Consumers’ Access to Prescription Medications, encouraging greater transparency, accountability, and a focus on measurable patient benefit across the prescription drug system. The comments address both pharmacy benefit manager practices and the federal 340B Drug Pricing Program, emphasizing the importance of understanding where prescription drug savings accrue and whether those savings ultimately benefit patients. The Study Committee continues its work this fall as it develops recommendations for the Georgia General Assembly. Read Georgia Life Sciences’ full comments →

Georgia Life Sciences Joins National Coalition Calling for PAHPA Reauthorization

September 22, 2026
Georgia Life Sciences (GLS) has joined more than 80 organizations from across industry, academia, public health and the biosecurity community in calling on congressional leaders to fully reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA) before the end of 2026. Led by the Johns Hopkins Center for Health Security, the coalition urged congressional leaders to advance a comprehensive reauthorization of PAHPA, the federal framework that supports the nation’s ability to prepare for and respond to public health emergencies and other health security threats. First enacted in 2006, PAHPA established and strengthened critical components of the nation’s health security infrastructure, including the Biomedical Advanced Research and Development Authority (BARDA). The law also supports public-private partnerships involved in the research, development, manufacturing and procurement of medical countermeasures, including vaccines, therapeutics and diagnostics. PAHPA’s authorization expired in 2023 and key provisions have since continued through short-term extensions. The coalition is calling for a comprehensive reauthorization that provides greater stability and ensures the nation’s preparedness infrastructure can continue adapting to emerging biological, infectious disease and other health security threats. For the life sciences industry, these programs are particularly important. Partnerships between government and industry can help move promising technologies from research through development and manufacturing while maintaining capabilities needed to respond quickly during an emergency. The Biotechnology Innovation Organization (BIO), also a signatory to the letter, has identified several priorities for reauthorization, including continued authorization of BARDA, the Strategic National Stockpile, Project BioShield and the Pandemic Influenza Program, as well as incentives supporting the development of medical countermeasures. Georgia Life Sciences is proud to join organizations across the country in supporting a strong and sustainable national framework for health security, preparedness and biomedical innovation. Read the coalition letter and view the full list of signatories.

Georgia Life Sciences Urges Protection of Patient Access as Georgia Implements Medicaid Changes

September 14, 2026
Georgia Life Sciences has submitted comments to the Georgia Department of Community Health (DCH) regarding the Georgia Pathways to Coverage program and implementation of new federal Medicaid requirements. As Georgia prepares for these changes, Georgia Life Sciences is urging state leaders to prioritize continuity of care and minimize unnecessary administrative barriers that could delay or disrupt access to medically necessary treatment . This is particularly important for Georgians living with serious, chronic, rare, and medically complex conditions who may rely on ongoing medications, diagnostics, therapies, medical technologies, specialty care, and coordinated treatment plans. Even temporary disruptions in coverage can interrupt care and create additional challenges for patients and families. In its comments, Georgia Life Sciences encouraged DCH to protect continuity of coverage during eligibility and redetermination processes, provide patients and caregivers with clear and timely information, minimize unnecessary administrative burdens, and establish appropriate safeguards when a coverage disruption could interrupt an established course of treatment. “As Georgia implements these new federal requirements, we want to ensure that patients remain at the center of the process,” said Maria Thacker Goethe, MPH, President & CEO of Georgia Life Sciences. “Administrative changes should not become barriers between patients and the care they need. Protecting continuity of care is particularly important for Georgians managing serious and complex health conditions.” Read Georgia Life Sciences’ full comments to DCH here.
MORE POSTS